Unlocking the Potential of FAM186B (C12orf25) as a Drug Target and Biomarker

Target Name: FAM186B

NCBI ID: G84070

FAM186B

Unlocking the Potential of FAM186B (C12orf25) as a Drug Target and Biomarker

Introduction

FAM186B (C12orf25) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is located in chromosome 12q34 and has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion . The identification of FAM186B as a potential drug target has significant implications for the development of new therapeutic approaches for various diseases.

FAM186B: A Putative Drug Target

FAM186B is a small non-coding RNA molecule that is expressed in various tissues and cells. It is a potential drug target because it has been shown to interact with several protein molecules, including the protein tyrosine kinase (TK) kinase. This interaction suggests that FAM186B may play a role in the regulation of cellular processes that are important for disease development, such as cell signaling pathways that contribute to cancer, neurodegenerative diseases, and autoimmune disorders.

FAM186B has been shown to interact with several proteins, including the TK kinase.

FAM186B as a Biomarker

FAM186B has also been identified as a potential biomarker for several diseases. Its expression has been shown to be downregulated in various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. This suggests that FAM186B may be a useful biomarker for the diagnosis and monitoring of these diseases.

FAM186B as a Potential therapeutic Target

The identification of FAM186B as a potential drug target has significant implications for the development of new therapeutic approaches for various diseases. By inhibiting the activity of FAM186B, researchers may be able to develop new treatments for diseases that are currently untreated or have limited treatment options.

FAM186B has also been shown to interact with several proteins, including the TK kinase. This suggests that FAM186B may be a useful target for small molecule inhibitors that can modulate the activity of TK kinase. These inhibitors could be used to treat diseases that are caused by the over-activity of TK kinase, such as neurodegenerative disorders and cancer.

Conclusion

In conclusion, FAM186B (C12orf25) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its interaction with the protein tyrosine kinase (TK) suggests that it may play a role in the regulation of cellular processes that are important for disease development. Further research is needed to fully understand the potential of FAM186B as a drug target and biomarker. By inhibiting the activity of FAM186B, researchers may be able to develop new treatments for various diseases.

Protein Name: Family With Sequence Similarity 186 Member B

The "FAM186B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM186B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets